Nearly everything written about people stopping these drugs treats it as a decision — the side effects were bad, the money ran out, the results disappointed. This survey asked people what actually happened, and much of it was not a decision at all. Cost still leads the list of stated reasons, but it is not the whole mechanism.
Read the sampling frame first
Invitations went to adults identified from one academic medical center’s records as having had at least one GLP-1 prescription in the preceding six years and a subsequent gap of more than 90 days. [1] So this is, by construction, a survey of people who had already discontinued. It was never a sample of everybody taking the drug.
Then 261 of 4,890 invited people responded — 5.3%. Whatever else is true, people with a grievance answer surveys about their grievance more often than people without one. Every percentage below describes those 261 respondents, and none of them is a rate for any wider population.
What respondents described
60.9% reported prior-authorization requirements. Among those, 49.7% either waited more than seven days or were never approved at all. Among people currently taking a weight-management medication, 32.4% reported a gap of two weeks or more.
The things that worked were interpersonal: 76.2% knew whom to contact about their medication, and 70.7% reported timely responses from their care team. The things that failed were structural: cross-clinic coordination at 54.1% and visibility into what needed to happen next at 52.2%.
The authors also built an exploratory Continuity-of-Care Index for this survey, scored 0 to 100. It averaged 69.5 across 242 respondents and differed sharply by where people were seen — a median of 82.1 at a dedicated weight-management clinic against 60.7 in primary care, Kruskal-Wallis p < 0.001. That is their own instrument rather than a standard measure, but the direction is plain enough.
What people said they wanted
Not more medicine. 89.5% wanted one place to track refills, prior authorization and appointments together, and 87.2% wanted to see prior-authorization status in real time. Those are requests for a status page.
What this does and does not argue for
It does not argue for buying from a website, and this site is not going to pretend otherwise. A cash purchase removes prior authorization by removing insurance, which is a genuine improvement on one axis and a loss on several others — no coverage if the price moves, no pharmacy network behind a stock-out, and no clinic to coordinate with because there is no clinic. That is the trade this market actually offers, stated plainly.
What it does argue is that some portion of what gets recorded as discontinuation is administrative rather than clinical, and that matters for how you read every persistence figure in this field. Even in a program where the drug was free, median persistence was under eleven months — cost is one mechanism among several, and so is paperwork.
If you are going the covered route, the practical reading is to expect the authorization to take time and to ask early. If you are going the cash route, the practical reading is that what you are buying is the absence of that process, priced accordingly — the coverage question is still worth exhausting first, and where you live changes both answers.